淋巴母细胞淋巴瘤
医学
病理
血管免疫母细胞性T细胞淋巴瘤
淋巴瘤
T细胞
T细胞淋巴瘤
淋巴
免疫学
免疫系统
作者
Robert S. Ohgami,Shuchun Zhao,Jane K. Ohgami,Matthew O. Leavitt,James L. Zehnder,Robert B. West,Daniel A. Arber,Yasodha Natkunam,Roger A. Warnke
标识
DOI:10.1097/pas.0b013e318264e223
摘要
T-lymphoblastic lymphoma is an aggressive neoplasm requiring prompt clinical treatment. Conversely, indolent T-lymphoblastic proliferation mimics T-lymphoblastic lymphoma but consists of a proliferation of non-neoplastic TdT+ T cells, requiring no treatment. Recently, we identified several cases of indolent T-lymphoblastic proliferations in extrathymic lymphoid tissues: 1 in a patient suffering from Castleman disease (CD) associated with a follicular dendritic cell sarcoma/tumor, 1 in a patient with a history of angioimmunoblastic T-cell lymphoma (AITL), and 1 in association with acinic cell carcinoma. Interestingly, in the case of the patient with a history of AITL, these TdT+ T cells were seen in multiple anatomic sites over the span of 5 years. Here we review these 3 cases and extend our findings by demonstrating that TdT+ T-lymphoblastic populations are increased in lymph nodes of patients with CD (P=0.011), CD in association with follicular dendritic cell tumors, and AITL (P<0.01) compared with other T-cell or B-cell lymphomas or reactive lymph nodes. Finally, analysis of 352 nonhematolymphoid tumors including carcinomas, melanomas, and sarcomas demonstrates that TdT+ T cells are not increased in these tumors. Our studies not only present several detailed cases of indolent T-lymphoblastic proliferations, but also correlate these populations with specific hematologic diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI